- Home
- WD vs OGN Comparison
WD vs OGN Comparison
Compare WD & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WD
- OGN
- Stock Information
- Founded
- WD 1937
- OGN 1923
- Country
- WD United States
- OGN United States
- Employees
- WD N/A
- OGN N/A
- Industry
- WD Finance: Consumer Services
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- WD Finance
- OGN Health Care
- Exchange
- WD Nasdaq
- OGN Nasdaq
- Market Cap
- WD 2.6B
- OGN 2.5B
- IPO Year
- WD 2010
- OGN N/A
- Fundamental
- Price
- WD $66.87
- OGN $9.76
- Analyst Decision
- WD Hold
- OGN Hold
- Analyst Count
- WD 3
- OGN 4
- Target Price
- WD $103.33
- OGN $18.00
- AVG Volume (30 Days)
- WD 230.0K
- OGN 4.6M
- Earning Date
- WD 08-07-2025
- OGN 08-05-2025
- Dividend Yield
- WD 4.00%
- OGN 8.77%
- EPS Growth
- WD 6.51
- OGN N/A
- EPS
- WD 2.92
- OGN 2.88
- Revenue
- WD $1,056,015,000.00
- OGN $6,294,000,000.00
- Revenue This Year
- WD $14.45
- OGN N/A
- Revenue Next Year
- WD $6.64
- OGN $1.11
- P/E Ratio
- WD $22.98
- OGN $3.41
- Revenue Growth
- WD 8.64
- OGN N/A
- 52 Week Low
- WD $64.48
- OGN $8.01
- 52 Week High
- WD $118.19
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- WD 40.14
- OGN 49.46
- Support Level
- WD $65.75
- OGN $9.88
- Resistance Level
- WD $71.90
- OGN $10.30
- Average True Range (ATR)
- WD 1.67
- OGN 0.38
- MACD
- WD 0.02
- OGN 0.11
- Stochastic Oscillator
- WD 18.21
- OGN 60.66
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.